

Supplementary Table 1. Prevalence and risk of developing different grades of Systemic and Local Adverse Effects Following Immunisation (S-AEFIs and L-AEFIs) with MVA-BN Vaccine up to six days from fitting a multinomial logistic regression according to administration route - intradermal (ID) vs subcutaneous (SC).

		Prevalence of S-AEFIs and OR (ID vs. SC) up to 6 days from vaccination					
Systemic symptoms	max severity	ID n (%)	SC n (%)	Unadjusted OR (95% CI) ID vs. SC	p-value	Adjusted* OR (95% CI) ID vs. SC	p-value
<i>Fatigue</i>	None	401 (56.0)	137 (60.9)	1	0.001	1	0.856
	Mild	174 (24.3)	35 (15.6)	1.70 (1.13, 2.56)		0.85 (0.37, 1.98)	
	Moderate	106 (14.8)	29 (12.9)	1.25 (0.79, 1.97)		1.41 (0.54, 3.69)	
	Severe	35 (4.9)	24 (10.7)	0.50 (0.29, 0.87)		1.20 (0.38, 3.81)	
<i>Headache</i>	None	500 (69.8)	166 (73.8)	1	0.022	1	0.065
	Mild	152 (21.2)	29 (12.9)	1.74 (1.13, 2.69)		2.66 (1.13, 6.27)	
	Moderate	47 (6.6)	22 (9.8)	0.71 (0.42, 1.21)		0.95 (0.25, 3.67)	
	Severe	17 (2.4)	8 (3.6)	0.71 (0.30, 1.66)		6.60 (0.68, 63.98)	
<i>Myalgia</i>	None	567 (79.2)	172 (76.4)	1	0.811	1	0.970
	Mild	92 (12.8)	32 (14.2)	0.87 (0.56, 1.35)		1.03 (0.39, 2.72)	
	Moderate	38 (5.3)	13 (5.8)	0.89 (0.46, 1.70)		1.11 (0.26, 4.73)	
	Severe	19 (2.7)	8 (3.6)	0.72 (0.31, 1.67)		1.47 (0.31, 6.94)	
<i>Nausea</i>	None	646 (90.2)	199 (88.4)	1	0.176	1	0.895
	Mild	49 (6.8)	15 (6.7)	1.01 (0.55, 1.83)		1.20 (0.31, 4.71)	
	Moderate	11 (1.5)	9 (4.0)	0.38 (0.15, 0.92)		0.53 (0.09, 3.02)	
	Severe	10 (1.4)	2 (0.9)	Nd		Nd	
<i>Chills</i>	None	656 (91.6)	202 (89.8)	1	0.260	1	0.803
	Mild	35 (4.9)	15 (6.7)	0.72 (0.38, 1.34)		0.89 (0.25, 3.09)	
	Moderate	13 (1.8)	7 (3.1)	0.57 (0.23, 1.45)		0.31 (0.03, 3.17)	
	Severe	12 (1.7)	1 (0.4)	Nd		Nd	
<i>Vomit</i>	None	710 (99.2)	219 (97.3)	1	0.559	1	0.993
	Mild	3 (0.4)	3 (1.3)	0.31 (0.06, 1.54)		Nd	
	Moderate	0 (0.0)	3 (1.3)	Nd		Nd	
	Severe	3 (0.4)	0 (0.0)	Nd		Nd	

		Prevalence of L-AEFIs and OR (ID vs. SC)					
Local symptoms	max severity	ID n (%)	SC n (%)	Unadjusted OR ID vs. SC	p-value	Adjusted* OR ID vs. SC	p-value
<i>Redness</i>	None	46 (6.5)	137 (60.9)	1	<.001	1	<0.001
	Mild	168 (23.6)	43 (19.1)	11.63 (7.25, 18.67)		20.84 (6.05, 71.73)	
	Moderate	325 (45.6)	25 (11.1)	38.72 (22.87, 65.54)		47.01 (13.15, 168.0)	
	Severe	173 (24.3)	20 (8.9)	25.76 (14.56, 45.59)		36.37 (9.90, 133.7)	
<i>Induration</i>	None	67 (9.4)	121 (53.8)	1	<.001	1	<0.001
	Mild	264 (37.1)	51 (22.7)	9.35 (6.12, 14.27)		10.84 (4.11, 28.57)	
	Moderate	281 (39.5)	36 (16.0)	14.10 (8.92, 22.28)		12.95 (4.55, 36.83)	
	Severe	100 (14.0)	17 (7.6)	10.62 (5.86, 19.25)		14.20 (4.28, 47.14)	
<i>Pain</i>	None	257 (36.1)	60 (26.7)	1	0.057	1	<0.001
	Mild	266 (37.4)	90 (40.0)	0.69 (0.48, 1.00)		0.21 (0.10, 0.48)	
	Moderate	147 (20.6)	58 (25.8)	0.59 (0.39, 0.90)		0.09 (0.03, 0.26)	
	Severe	42 (5.9)	17 (7.6)	0.58 (0.31, 1.08)		0.37 (0.09, 1.45)	

* Adjusted for age and HIV status; 95 CI: 95% Confidence Interval; Nd: not determined